- source： CentryMed
- author： CentryMed
-
2025.08.28
On August 27-28, the 19th Sullivan Global Growth, Innovation, and Leadership Summit and the 4th New Investment Conference were held in Shanghai. Dr. Xiaozuo Xiang, Chairman and General Manager of Shimai Pharmaceutical, was invited to attend the conference and gave a keynote speech on "TCE Technology Development and Latest Trends" at the Life Science New Investment Summit Forum - Biomedical Special Event of the New Investment Conference.
In the speech, the chairman elaborated on the current status of solid tumor treatment from the perspective of the rapidly increasing number of global cancer patients. He pointed out that drug resistance and safety issues are currently the two core challenges in the treatment of malignant solid tumors. To solve these problems and challenges, bispecific antibodies, which are more specific and targeted than monoclonal antibody drugs, are gradually entering the public's field of vision. He believes that TCE (T-Cell Engager) drugs have become a shining star in the field of cancer treatment due to their efficient activation of T cells and precise killing of tumor cells. TCE dual antibody is about to trigger a new storm in the field of solid tumor treatment, and the next generation of solid tumor T cell adapters will become the opening work of China's innovative global value, becoming the next "billion dollar blue ocean" in the world.
At the meeting, the chairman also shared the latest innovative trends in TCE technology such as conditional activation TCE strategy (protease activated TCE, etc.), multispecific design (trispecific TCEs), AI driven development, as well as the experience and achievements of Shimai Pharmaceutical in the TCE field for many years, which received praise and attention from attending experts and investors.
WeChat ID | shimaiyaoye Official Website | m.xzzldc.cn
>